ADHD Prescription digital tools

Intervention Maps · ADHD · Prescription digital therapeutics

What can a prescription ADHD video game actually do?

Bottom line

One prescription video-game treatment has shown a narrow improvement on a computerized attention test in children studied under defined conditions. The main trial did not show the same clear advantage on broader parent or clinician ADHD ratings. Authorization is real, but it does not mean broad symptom relief, stand-alone care, or that every ADHD app works.

What the main trial found

Children ages 8 to 12 played either the prescription treatment or a comparison game at home for about four weeks. The treatment group improved more on the trial’s main computerized measure of attention.

That is a genuine result. On broader ADHD rating scales, however, the treatment did not show a clear advantage over the comparison game. Better performance on an attention test and noticeable improvement in everyday ADHD behavior are related questions, not interchangeable ones.

What authorization means

Regulatory authorization applies to a specific product, for a specific age group, under specific conditions. It does not automatically extend to other apps or broader treatment claims.

The product is intended to be used as part of a therapeutic program, not as stand-alone care. Authorization does not mean it matches stimulant effects, improves every typical ADHD behavior, or replaces clinician-directed treatment and educational support.

Keep three technologies separate

This prescription treatment is not the same as a generic brain-training app or neurofeedback. Each has different trials and different limits. A result for one product cannot be borrowed by every game that promises focus.

What remains uncertain

We still need better answers about durability, school and home functioning, how often test improvements matter to families, and whether future controlled trials will close the gap between attention testing and everyday symptom ratings.

Evidence consulted Open sources

Key sources used to prepare this answer. Product indications and authorizations can change.

  1. Kollins et al. STARS-ADHD randomized trial of AKL-T01 (2020)
  2. FDA 510(k) summary for EndeavorRx, including the ages 8 to 17 indication (2023)

← Back to ADHD · find this again later from “What are you trying to figure out?”